厄贝沙坦联合左卡尼汀治疗维持性血液透析患者心力衰竭的疗效观察

目的探讨厄贝沙坦联合左卡尼汀治疗维持性血液透析患者心力衰竭的疗效。方法 60例行维持性血液透析合并心力衰竭的患者分为观察组和对照组各30例,两组均在充分透析的基础上予强心、扩血管及厄贝沙坦每日150 mg口服,左卡尼汀1.0 g静脉注射,连用1个月后评价心功能。结果治疗后,观察组患者的CI、LVEF分别较治疗前及对照组明显升高,组间比较差异有统计学意义(P<0.05)。治疗1个月后,观察组的临床总有效率93.3%,明显高于对照组(χ2=7.132,P<0.05)。观察组治疗后的有效率达40%,与对照组比较差异不显著(χ2=2.265,P>0.05)。结论厄贝沙坦联合左卡尼汀治疗维持性血液透析患者心力衰竭疗效确切,安全性较好,可明显改善患者的心功能,值得推广和应用。

The efficacy of irbesartan combined L-carnitine in treatment of maintenance hemodialysis patients with heart failure

Objective To investigate the efficacy of irbesartan combined L-carnitine in treatment of maintenance hemodialysis patients with heart failure. Methods Sixty hemodialysis patients with heart failure were divided into observation group and control group of 30 patients in each. The two groups were given full cardiac, vasodilator therapy on the basis of hemodialysis,and were given irbesartan 150 mg/d, oral, L-carnitine 1.0g iv, after treatment a month,the cardiac function were compared. Results After treatment, CI, LVEF of the observation group patients were compared with the before treatment and the control group significantly increased,the difference was significant between the two groups（P 〈 0.05）. After 1 month of treatment,clinical total effective rate of observation group was 93.3%,was significantly higher than the control group （X2=7.132, P 〈 0.05）. The effective rate of observation group was 40% ,compared with the control group,the difference was not significant （X2=2.265, P 〉 0.05）. Conclusion Irbesartan combined L-carnitine in treatment of maintenance hemodialysis patients with heart failure has better safety, can significantly improve cardiac function in patients, should be promoted and applied.